Document:

Performance Unit Agreement

 Exhibit 10.28 
 Form of Award Notice 
 This notice of Award (the “Award
Notice”) sets forth certain details relating to the grant by the Company to you of the Award identified below, pursuant to the Plan. The terms of this Award Notice are incorporated into the Agreement that accompanies this Award Notice and
made of part of the Agreement. Capitalized terms used in this Award Notice that are not otherwise defined in this Award Notice have the meanings given to such terms in the Agreement. 

 

			
	 Employee:
	  	 Kevin W. Sharer

	 Employee ID:
	  	 XXXX

	 Address:
	  	 XXX XXXXXX XXXXXX

		  	 XXX XXXXXXX, XX XXXXX

	 Award Type:
	  	 Performance Unit

	 Grant ID:
	  	 DP0561

	 Plan:
	  	 Amgen Inc. 2009 Equity Incentive Plan

	 Program
	  	 Amgen Inc. 2009 Performance Award Program

	 Grant Date:
	  	 April 27, 2012

	 Number of Shares:
	  	 35,734

	 Number of
	  	
	 Performance Units:
	  	 35,734

	 Resolutions:
	  	 The Resolutions of the Compensation and Management Development Committee of the Board of Directors of Amgen Inc., adopted on March 14, 2012, regarding the Amgen
Inc. 2009 Performance Award Program. (Pursuant to the Resolutions, Article VII of the Amgen Inc. 2009 Performance Award Program shall not apply to this Agreement.)

	 Performance Period:
	  	 The Performance Period beginning on January 1, 2012 and ending on December 31, 2014.

	 Vesting Date:
	  	 Means the vesting date indicated in the Vesting Schedule

	 Vesting Schedule:
	  	 Means the schedule of vesting set forth under Vesting Details

	 Vesting Details:
	  	 Means the presentation (tabular or otherwise) of the Vesting Date and the quantity of Shares vesting.

  

					
	  	 	 Vesting Date
	  	 Quantity Vesting

	 	April 27, 2015	  	35,734

 PERFORMANCE UNIT AGREEMENT 

THE SPECIFIC TERMS OF YOUR GRANT OF PERFORMANCE UNITS ARE FOUND IN THE PAGES RELATING TO THE GRANT OF PERFORMANCE UNITS FOUND ON
MERRILL LYNCH BENEFITS WEBSITE (OR THE WEBSITE OF ANY SUCCESSOR COMPANY TO MERRILL LYNCH BANK & TRUST CO., FSB) (THE “AWARD NOTICE”) WHICH ACCOMPANIES THIS DOCUMENT. THE TERMS OF THE AWARD NOTICE ARE INCORPORATED INTO THIS
PERFORMANCE UNIT AGREEMENT. 
 On the Grant Date specified in the Award Notice, Amgen Inc., a Delaware
corporation (the “Company”), has granted to you, the grantee named in the Award Notice, under the plan specified in the Award Notice (the “Plan”), the Number of Performance Units (the “Performance
Units”) specified in the Award Notice on the terms and conditions set forth in this Performance Unit Agreement (and any applicable special terms and conditions for your country set forth in the attached Appendix A (as described in
greater detail in Section XV below)) (collectively, this “Agreement”), the Plan, the Amgen Inc. 2009 Performance Award Program (the “Program”) and the Resolutions (as defined below). Capitalized terms not defined herein
shall have the meanings assigned to such terms in the Program. 
 I. Performance Period. The Performance
Period shall have the meaning set forth in the Award Notice. 
 II. Value of Performance Units. The value
of each Performance Unit is equal to a share of Common Stock. 
 III. Performance Goals. An amount of the
Performance Units up to the maximum amount specified in the Resolutions shall be earned, depending on the extent to which the Company achieves objectively determinable Performance Goals established by the Committee pursuant to the
Resolutions. The Performance Units earned shall be calculated in accordance with the Resolutions and the Program. 
 IV. Form and Timing of Payment. Subject to Section XIV and except as set forth in the Program, for any Performance Units earned pursuant to Section III above, the specified payment date applicable
to such Performance Units shall be the year immediately following the end of the Performance Period. Shares of Common Stock issued in respect of a Performance Unit shall be deemed to be issued in consideration of past services actually rendered by
you to the Company or an Affiliate or for its benefit for which you have not previously been compensated or for future services to be rendered, as the case may be, which the Company deems to have a value at least equal to the aggregate par value
thereof. 
 V. Issuance of Certificates; Tax Withholding. Regardless of any action the Company or your
actual employer (the “Employer”) takes with respect to any or all income tax (including federal, state and local taxes), social insurance, payroll tax, payment on account or other tax-related items related to your participation in the Plan
and the Program and legally applicable to you (the “Tax Obligations”), you acknowledge that the ultimate liability for all Tax Obligations 

  
 1 

 
is and remains your responsibility and may exceed the amount actually withheld by the Company and/or your Employer. You further acknowledge that the Company and/or your Employer (i) make no
representations or undertakings regarding the treatment of any Tax Obligations in connection with any aspect of the Performance Units, including the grant of the Performance Units, the vesting of the Performance Units, the conversion of the
Performance Units into shares or the receipt of an equivalent cash payment, the subsequent sale of any shares acquired at settlement and the receipt of any dividends; and (ii) do not commit to and are under no obligation to structure the terms
of the grant or any aspect of the Performance Units to reduce or eliminate your liability for Tax Obligations or to achieve any particular tax result. Furthermore, if you become subject to tax in more than one jurisdiction between the Grant Date and
the date of any relevant taxable event, you acknowledge that the Company and/or your Employer (or former employer, as applicable) may be required to withhold or account for Tax Obligations in more than one jurisdiction. 

Prior to any relevant taxable or tax withholding event, as applicable, you shall pay or make adequate arrangements
satisfactory to the Company or to your Employer (in their sole discretion) to satisfy all Tax Obligations. In this regard, you authorize the Company and/ or your Employer, or their respective agents, at their discretion, to satisfy all applicable
Tax Obligations by one or a combination of the following: 
 (a) withholding from your wages or other cash
compensation paid to you by the Company and/or your Employer; or 
 (b) withholding from proceeds of the sale of
shares of Common Stock issued upon settlement of the Performance Units, either through a voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization); or 

(c) withholding in shares of Common Stock to be issued upon settlement of the Performance Units provided that the Company
and your Employer shall only withhold an amount of shares of Common Stock with a fair market value equal to the Tax Obligations. 
 To avoid adverse accounting treatment, the Company may withhold or account for Tax Obligations not to exceed the applicable minimum statutory withholding rates or other applicable withholding rates. If
the Tax Obligations are satisfied by withholding in shares of Common Stock, for tax purposes, you are deemed to have been issued the full number of shares subject to the earned Performance Units, notwithstanding that a number of shares of Common
Stock is held back solely for the purpose of paying the Tax Obligations due as a result of any aspect of your participation in the Plan (any shares of Common Stock withheld by the Company hereunder shall not be deemed to have been issued by the
Company for any purpose under the Plan and shall remain available for issuance thereunder). 
 Finally, you
shall pay to the Company or your Employer any amount of Tax Obligations that the Company or your Employer may be required to withhold or account for as a result of your participation in the Plan and the Program that cannot be satisfied by the means
previously described. You agree to take any further actions and to execute any additional documents as may be necessary to effectuate the provisions of this Section V. Notwithstanding Section IV above, the Company may refuse to issue or deliver the
shares of Common Stock or the proceeds of the sale of shares of Common Stock if you fail to comply with your obligations in connection with the Tax Obligations. 

  
 2 

 VI. Dividend Equivalents 

(a) Crediting of Dividend Equivalents. Subject to this Section VI, Dividend Equivalents shall be credited on each
Performance Unit granted to you under this Agreement in the manner set forth in the remainder of this Section VI. If the Company declares one or more dividends or distributions (each, a “Dividend”) on its Common Stock with a record date
which occurs during the period commencing on the Grant Date through and including the day immediately preceding the day the shares of Common Stock subject to the Performance Units are issued to you, whether in the form of cash, Common Stock or other
property, then as of the date the number of Performance Units payable to you pursuant to the terms this Agreement are determined and payable, you shall be credited with an amount equal to the amount or fair market value of such Dividend which would
have been payable to you if you held a number of shares of Common Stock equal to the number of Performance Units payable to you as of each such record date for each such Dividend (not including on any Performance Units which were previously paid or
forfeited) as if each such amount had been reinvested in Common Stock as of the date of the payment of such Dividend. Each such Dividend Equivalent shall be deemed to have been reinvested in the Common Stock as of the Dividend payment date. Dividend
Equivalents shall be payable in full shares of Common Stock, unless the Administrator determines, at any time prior to payment and in its discretion, that they shall be payable in cash. Dividend Equivalents payable with respect to fractional shares
of Common Stock shall be paid in cash. 
 (b) Treatment of Dividend Equivalents. Except as otherwise
expressly provided in this Section VI any Dividend Equivalents credited to you shall be subject to all of the provisions of this Agreement which apply to the Performance Units with respect to which they have been credited and shall be payable, if at
all, at the time and to the extent that the underlying Performance Unit becomes payable. Dividend Equivalents shall not be payable on any Performance Units that do not vest, or are forfeited, pursuant to the terms of this Agreement. 

VII. Termination of Your Employment During Performance Period. 

(a) In the event that your employment with the Company or an Affiliate is terminated prior to the last business day of a
Performance Period by reason of your Voluntary Retirement and you are Retirement-Eligible on the date of such termination, the full amount of your Award, if any, applicable to such Performance Period, shall be paid in accordance with the provisions
of Article VI of the Performance Program. For purposes of the foregoing, your Award (rounded down to the nearest whole number) shall be determined based on the Company’s performance as compared to the Performance Goals for such Performance
Period and the full amount of the Award shall be payable. Notwithstanding the foregoing, you shall not be entitled to your Award pursuant to this Section VII(a), unless either you sign a general release and waiver in a form provided by the Company
and deliver it to the Company no later than the date specified by the Company, or the Company waives such release requirement in writing; provided, however, that in no event shall payment of your Award be made later than the specified
payment date as set forth in Section 6.1 of the Performance Program. 

  
 3 

 (b) In the event that your employment with the Company or an Affiliate is
terminated prior to the last business day of a Performance Period by reason of your death or Permanent and Total Disability, your Award, if any, applicable to such Performance Period, shall be paid in accordance with the provisions of Article VI of
the Performance Program. For purposes of the foregoing, the amount of your Award (rounded down to the nearest whole number) shall be determined based on the Company’s performance as compared to the Performance Goals for such Performance Period
and the full amount of such Award shall be payable. Notwithstanding the foregoing, if your employment is terminated due to your Permanent and Total Disability, you shall not be entitled to your Award pursuant to this Section VII(b), unless either
you sign a general release and waiver in a form provided by the Company and deliver it to the Company no later than the date specified by the Company, or the Company waives such release requirement in writing; provided, however, that
in no event shall payment of your Award be made later than the specified payment date as set forth in Section 6.1 of the Performance Program. 
 (c) In the event that your employment with the Company or an Affiliate is terminated prior to the last business day of a Performance Period for any reason other than as specified in Section VII(a) and
Section VII(b) above, all of your rights to an Award for such Performance Period shall be forfeited, unless, prior to the payment date described in Article VI of the Performance Program, the Company, in its sole discretion, makes a written
determination to otherwise pay the full amount of your Award, if any, applicable to such Performance Period, which amount shall be paid in accordance with the provisions of Article VI of the Performance Program. Notwithstanding the foregoing, you
shall not be entitled to your Award pursuant to this Section VII(c), unless either your sign a general release and waiver in a form provided by the Company and deliver it to the Company no later than the date specified by the Company, or the Company
waives such release requirement in writing; provided, however, that in no event shall payment of your Award be made later than the specified payment date as set forth in Section 6.1 of the Performance Program. 

(d) In the event that your employment with the Company or an Affiliate is terminated on or after the last business day of
the applicable Performance Period but prior to the Determination Date for any reason, you shall be paid the amount of any Award applicable to such Performance Period in accordance with the provisions of Article VI of the Performance Program.

 VIII. Nontransferability. No benefit payable under, or interest in, this Agreement or in the shares of
Common Stock that may become issuable to you hereunder shall be subject in any manner to anticipation, alienation, sale, transfer, assignment, pledge, encumbrance or charge and any such attempted action shall be void and no such benefit or interest
shall be, in any manner, liable for, or subject to, your or your beneficiary’s debts, contracts, liabilities or torts; provided, however, nothing in this Section VIII shall prevent transfer (i) by will or (ii) by applicable
laws of descent and distribution. 
 IX. No Contract for Employment. This Agreement is not an employment
or service contract with the Company or an Affiliate and nothing in this Agreement shall be deemed to create in any way whatsoever any obligation on your part to continue in the employ or service of the Company or an Affiliate, or of the Company or
an Affiliate to continue your employment or service with the Company or an Affiliate. 

  
 4 

 X. Nature of Grant. In accepting the grant of Performance Units, you
acknowledge that: 
 (a) the Plan and the Program are established voluntarily by the Company, are discretionary
in nature and may be modified, amended, suspended or terminated by the Company at any time, as provided in the Plan and in the Program; 
 (b) the grant of the Performance Units is voluntary and occasional and does not create any contractual or other right to receive future awards of Performance Units, or benefits in lieu of Performance
Units, even if Performance Units have been awarded repeatedly in the past; 
 (c) all decisions with respect to
future awards, if any, will be at the sole discretion of the Company; 
 (d) your participation in the Plan and
the Program shall not create a right to further employment with the Employer and shall not interfere with the ability of the Employer to terminate your employment or service relationship (if any) at any time; 

(e) your participation in the Plan and the Program is voluntary; 

(f) the grant of Performance Units and the shares of Common Stock subject to the Performance Units are not intended to
replace any pension rights or compensation; 
 (g) neither the grant of Performance Units nor any provision of
this Agreement, the Plan, the Program or the policies adopted pursuant to the Plan or Program confer upon you any right with respect to employment or continuation of current employment and shall not be interpreted to form an employment contract or
relationship with the Company or any Affiliate of the Company; 
 (h) the future value of the shares of Common
Stock that may be earned upon the end of the Performance Period is unknown and cannot be predicted with certainty; 
 (i) in consideration of the grant of Performance Units hereunder, no claim or entitlement to compensation or damages shall arise from forfeiture of the Performance Units resulting from termination of your
employment by the Company or an Affiliate of the Company (for any reason whatsoever and whether or not in breach of local labor laws) and you irrevocably release the Company and your Employer from any such claim that may arise; if, notwithstanding
the foregoing, any such claim is found by a court of competent jurisdiction to have arisen, you shall be deemed irrevocably to have waived your entitlement to pursue such claim; 

(j) in the event of termination of your employment (whether or not in breach of local labor laws), your right to receive
Performance Units and receive shares under the Plan and the Program, if any, will terminate effective as of the date that you are no longer actively employed and will not be extended by any notice period mandated under local law (e.g., active
employment would not include a period of “garden leave” or similar period pursuant to local law); 

  
 5 

 (k) except as otherwise provided in this Agreement or the Plan, the
Performance Units and the benefits evidenced by this Agreement do not create any entitlement to have the Performance Units or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in
connection with any corporate transaction affecting the shares of the Company; and 
 (l) the following
provisions apply only if you are providing services outside the United States: 
 (A) for employment law
purposes outside the United States, the Performance Units and underlying shares of Common Stock are not part of normal or expected compensation or salary for any purpose, including but not limited to for purposes of calculating any severance,
resignation, termination, redundancy, dismissal, end of service payments, bonuses, holiday pay, long-service awards, pension or retirement benefits or similar payments; and 

(B) you acknowledge and agree that neither the Company, the Employer nor any Affiliate of the Company shall be liable
for any foreign exchange rate fluctuation between your local currency and the United States Dollar that may affect the value of the Performance Units or of any amounts due to you pursuant to the settlement of the Performance Units or the subsequent
sale of any shares of Common Stock acquired upon settlement. 
 XI. No Advice Regarding Grant. The
Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding your participation in the Plan and the Program, or your acquisition or sale of the underlying shares of Common Stock. You are hereby
advised to consult with your personal tax, legal and financial advisors regarding your participation in the Plan and the Program before taking any action related thereto. 

XII. Notices. Any notices provided for in this Agreement, the Plan or the Program shall be given in writing or
electronically and shall be deemed effectively given upon receipt or, in the case of notices delivered by the Company to you, five (5) days after deposit in the United States mail, postage prepaid, addressed to you at such address as is
currently maintained in the Company’s records or at such other address as you hereafter designate by written notice to the Company Stock Administrator. Such notices may be given using any automated system for the documentation, granting or
exercise of Awards, such as a system using an internet website or interactive voice response, as approved by the Company. 
 XIII. Resolutions, Plan and Program. This Agreement is subject to all the provisions of the Resolutions, the Plan and the Program and their provisions are hereby made a part of this Agreement and
incorporated herein by reference, including, without limitation, the provisions of 

  
 6 

 
Articles 5 and 9 of the Plan (relating to Performance-Based Compensation and Performance Awards, respectively) and Section 13.2 of the Plan (relating to adjustments upon changes in the
Common Stock), and is further subject to all interpretations, amendments, rules and regulations which may from time to time be promulgated and adopted pursuant to the Plan. In the event of any conflict between the provisions of this Agreement and
those of the Resolutions, the Plan and the Program, the provisions of the Plan shall control. Notwithstanding any provision of this Agreement or the Program to the contrary, any earned Performance Units paid in cash rather than shares of Common
Stock shall not be deemed to have been issued by the Company for any purpose under the Plan. 
 XIV. No
Compensation Deferral. The Performance Units are not intended to constitute “nonqualified deferred compensation” within the meaning of Section 409A of the U.S. Internal Revenue Code of 1986, as amended from time to
time (together with the regulations and official guidance promulgated thereunder, the “Code”). However, if at any time the Committee determines that the Performance Units may be subject to Section 409A of the Code,
the Committee shall have the right, in its sole discretion, and without your prior consent to amend the Program as it may determine is necessary or desirable either for the Performance Units to be exempt from the application of
Section 409A of the Code or to satisfy the requirements of Section 409A of the Code, including by adding conditions with respect to the vesting and/or the payment of the Performance Units, provided that no such amendment may change the
Program’s “performance goals,” within the meaning of Section 162(m) of the Code, with respect to any person who is a “covered employee,” within the meaning of Section 162(m) of the Code. Any such amendment to the
Program may in the Committee’s sole discretion apply retroactively to this award of Performance Units. 

XV. Provisions Applicable to Participants in Foreign Jurisdictions. Notwithstanding any provision of this
Agreement or the Program to the contrary, if you are employed by the Company or an Affiliate in any of the countries identified in the attached Appendix A (which constitutes a part of this Agreement), are subject to the laws of any foreign
jurisdiction, or relocate to one of the countries included in the attached Appendix A, your award of Performance Units shall be subject to any special terms and conditions for such country set forth in Appendix A and to the following
additional terms and conditions: 
  

	 	(a)	 the terms and conditions of this Agreement, including Appendix A, are deemed modified to the extent necessary or advisable to comply with
applicable foreign laws or facilitate the administration of the Plan and the Program; 

  

	 	(b)	 if applicable, the effectiveness of your Award is conditioned upon its compliance with any applicable foreign laws, regulations, rules or local
governmental regulatory exemption and subject to receipt of any required foreign regulatory approvals; 

  

	 	(c)	 to the extent necessary to comply with applicable foreign laws, the payment of any earned Performance Units shall be made in cash or Common Stock,
at the Company’s election; and 

  
 7 

 (d) the Committee may take any other action, before or after an award of
Performance Units is made, that it deems necessary or advisable to obtain approval or comply with any necessary local governmental regulatory exemptions or approvals. 

Notwithstanding the foregoing, the Committee may not take any actions hereunder, and no award of Performance Units shall
be granted, that would violate the Securities Act, the Exchange Act, the Code, or any other securities or tax or other applicable law or regulation. Notwithstanding anything to the contrary contained herein, the shares issuable upon vesting of the
Performance Units shall not be issued unless such shares are then registered under the Securities Act, or, if such shares are not then so registered, the Company has determined that such exercise and issuance would be exempt from the registration
requirements of the Securities Act. 
 XVI. Data Privacy and Notice of Consent. You
hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement by and among, as applicable, the Employer, the Company, and any Affiliates of the
Company for the exclusive purpose of implementing, administering and managing your participation in the Plan and the Program. 
 You understand that the Company and the Employer may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social
insurance number (to the extent permitted under applicable local law) or other identification number, salary, nationality, job title, residency status, any shares of stock or directorships held in the Company, details of all equity compensation or
any other entitlement to shares awarded, canceled, vested, unvested or outstanding in your favor, for the purpose of implementing, administering and managing the Plan and the Program (“Data”). 

You understand that Data may be transferred to Merrill Lynch Bank & Trust Co., FSB (or any successor
thereto), any third parties assisting in the implementation, administration and management of the Plan and the Program, that these recipients may be located in your country, or elsewhere, including outside the European Economic Area and that the
recipient’s country (e.g., the United States) may have different data privacy laws and protections than your country. You understand that if you reside outside the United States, you may request a list with the names and addresses of any
potential recipients of the Data by contacting your local human resources representative. You authorize the Employer, the Company, Affiliates of the Company, Merrill Lynch Bank & Trust Co., FSB (or any successor thereto), and any other
possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing your participation in the Plan and the Program to receive, possess, use, retain and transfer the Data, in electronic or other
form, for the purposes of implementing, administering and managing your participation in the Plan and the Program, including any requisite transfer of such Data as may be required to a broker, escrow agent or other third party with whom the shares
received upon vesting of the Performance Units may be deposited. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan and the Program. You understand that if you reside
outside the United States, you may, at any time, view Data, request additional information about the storage and processing of Data, require 

  
 8 

 
any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand
that you are providing the consents herein on a purely voluntary basis. If you do not consent, or if you later seek to revoke your consent, your employment status or service and career with the Employer will not be adversely affected; the only
adverse consequence of refusing or withdrawing your consent is that the Company would not be able to grant you Performance Units or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing
your consent may affect your ability to participate in the Plan and the Program. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources
representative. 
 XVII. Language. If you have received this Agreement or any other document
related to the Plan and/or the Program translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control. 

XVIII. Governing Law. The terms of this Agreement shall be governed by the laws of the State of Delaware without
giving effect to principles of conflicts of laws. For purposes of litigating any dispute that arises hereunder, the parties hereby submit to and consent to the jurisdiction of the State of Delaware, and agree that such litigation shall be conducted
in the courts of the State of Delaware, or the federal courts for the United States for the federal district located in the State of Delaware, and no other courts, where this Agreement is made and/or to be performed. 

XIX. Severability. If one or more of the provisions of this Agreement shall be held invalid, illegal or
unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or unenforceable provisions shall be deemed null and void; however, to
the extent permissible by law, any provisions which could be deemed null and void shall first be construed, interpreted or revised retroactively to permit this Agreement to be construed so as to foster the intent of this Agreement and the Plan.

 XX. Electronic Delivery The Company may, in its sole discretion, decide to deliver any documents
related to current or future participation in the Plan and/or the Program by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system
established and maintained by the Company or another third party designated by the Company. 
 XXI.
Imposition of Other Requirements. The Company reserves the right to impose other requirements on your participation in the Plan and the Program, on the Performance Units and on any shares of Common Stock acquired under the Plan and the
Program, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing. 

  
 9 

 XXII. Waiver. You acknowledge that a waiver by the Company of breach
of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by you or any other grantee. 

 

			
	 Very truly yours,

	
	 AMGEN INC.

		
	 By:
	 	 /s/ David J. Scott

	 Name:
	 	 David J. Scott

	 Title:
	 	 Senior Vice President
 General Counsel and Secretary

  

			
	 Accepted and Agreed,
 this 9th day of July, 2012.

		
	 By:
	 	 /s/ Kevin W. Sharer

		 	 Kevin W. Sharer

  
 10 

 APPENDIX A 

ADDITIONAL TERMS AND CONDITIONS OF THE 
 AMGEN INC. 2009 EQUITY INCENTIVE PLAN 
 AWARD OF PERFORMANCE UNITS

 (BY COUNTRY) 
 TERMS AND CONDITIONS 
 This Appendix includes additional terms and
conditions that govern any Performance Units granted under the Plan if, under applicable law, you are a resident of, or are deemed to be a resident of one of the countries listed below. Furthermore, the additional terms and
conditions that govern the Performance Units granted hereunder may apply to you if you relocate to one of the countries listed below and the Company shall, in its discretion, determine to what extent the terms and conditions contained herein shall
apply to you. Certain capitalized terms used but not defined in this Appendix A shall have the meanings set forth in the Plan and/or the Agreement to which this Appendix is attached. 
 NOTIFICATIONS 
 This Appendix also includes notifications relating to
exchange control and other issues of which you should be aware with respect to your participation in the Plan. The information is based on the exchange control, securities and other laws in effect in the countries to which this Appendix refers as of
February 2012. Such laws are often complex and change frequently. As a result, the Company strongly recommends that you not rely on the notifications herein as the only source of information relating to the consequences of your participation in the
Plan because the information may be outdated when you acquire shares of Common Stock under the Plan, or when you subsequently sell shares of Common Stock acquired under the Plan. 

In addition, the notifications are general in nature and may not apply to your particular situation, and the Company is not in a position
to assure you of any particular result. Accordingly, you are advised to seek appropriate professional advice as to how the relevant laws in your country may apply to your situation. Finally, if you are a citizen or resident of a country other than
the one in which you are currently working or are considered a resident of another country for local law purposes, the information contained herein may not be applicable to you or you may be subject to the provisions of one or more jurisdictions.

  
 Appendix- 1

 ALGERIA 
 NOTIFICATIONS 
 Exchange Control Information. Proceeds from the sale of Shares
and any cash dividends must be repatriated to Algeria. 
 AUSTRALIA 

NOTIFICATIONS 

Exchange Control Information. Exchange control reporting is required for cash transactions exceeding AUD10,000 and for
international fund transfers. If an Australian bank is assisting with the transaction, the bank will file the report on your behalf.  
 Securities Law Information. If you acquire shares of Common Stock under the Plan and offer the shares of Common Stock for sale to a person or entity resident in Australia, the offer may be subject
to disclosure requirements under Australian law. You should consult with your own legal advisor before making any such offer in Australia. 

AUSTRIA 
 NOTIFICATIONS

 Consumer Protection Information. You may be entitled to revoke acceptance of the Award on the basis of the
Austrian Consumer Protection Act (the “Act”) under the conditions listed below, if the Act is considered to be applicable to the Award, the Plan and the Program: 

 

	 	(i)	 If you accept the Award outside the business premises of the Company, you may be entitled to revoke your acceptance of the Award, provided the
revocation is made within one (1) week after such acceptance of an Award. 

  

	 	(ii)	 The revocation must be in written form to be valid. It is sufficient if you return the Agreement to the Company or the Company’s representative
with language which can be understood as a refusal to conclude or honor the Agreement, provided the revocation is sent within the period discussed above. 

 Exchange Control Information. If you hold shares of Common Stock acquired under the Plan outside of Austria, you must submit a report to the Austrian National Bank. An exemption applies if the
value of the shares as of any given quarter does not exceed €30,000,000 or if the value of the shares in any given year as of December 31 does not exceed €5,000,000. If the former threshold is exceeded, quarterly obligations are
imposed, whereas if the latter threshold is exceeded, annual reports must be given. The annual reporting date is December 31 and the deadline for filing the annual report is March 31 of the following year. 

  
 Appendix- 2

 A separate reporting requirement applies when you sell shares of Common Stock acquired under
the Plan. In that case, there may be exchange control obligations if the cash proceeds are held outside of Austria. If the transaction volume of all accounts abroad exceeds €3,000,000, the movements and balances of all accounts must be reported
monthly, as of the last day of the month, on or before the 15th day of the following month, on the prescribed form (Meldungen SI-Forderungen und/oder SI-Verpflichtungen). 
 BELGIUM 
 NOTIFICATIONS 

Tax Reporting Notification. You are required to report any taxable income attributable to the Award granted hereunder on your
annual tax return. You are also required to report any security and bank accounts opened and maintained outside Belgium on your annual tax return. 
 BRAZIL 
 TERMS AND CONDITIONS 

Compliance with Law. By accepting the Performance Units, you acknowledge that you agree to comply with applicable Brazilian laws
and pay any and all applicable taxes associated with the vesting of the Performance Units and the sale of shares of Common Stock acquired under the Plan. 
 NOTIFICATIONS 
 Exchange Control Information. If you are
resident or domiciled in Brazil, you will be required to submit annually a declaration of assets and rights held outside of Brazil to the Central Bank of Brazil if the aggregate value of such assets and rights equals or exceeds US$100,000. Assets
and rights that must be reported include the shares of Common Stock. 
 BULGARIA 

There are no country-specific provisions. 

CANADA 
 TERMS AND
CONDITIONS 
 Termination of Service. This provision supplements Section X(j) of the Agreement: 

In the event of involuntary termination of your employment (whether or not in breach of local labor laws), your right to receive an Award
and vest in such Award under the Plan and the Program, if any, will terminate effective as of the date that is the earlier of: (1) the date you receive notice of termination of employment from the Company or your Employer, or (2) the date
you are no longer actively employed by the Company or your Employer regardless of any notice period or period of pay in lieu of such notice required under local law (including, but not 

  
 Appendix- 3

 
limited to statutory law, regulatory law and/or common law). Your right, if any, to acquire shares of Common Stock pursuant to an Award after termination of employment will be measured by the
date of termination of your active employment and will not be extended by any notice period mandated under local law. 
 Form
of Settlement - Performance Units Payable Only in Shares. Notwithstanding any discretion in the Plan or the Program or anything to the contrary in the Agreement, the Award does not provide any right for you, as a resident of Canada, to
receive a cash payment and shall be paid in Shares only. 
 The following provisions will apply to you if you are a resident of Quebec:

 Language Consent. The parties acknowledge that it is their express wish that the Agreement, as well as all
documents, notices, and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English. 
 Les parties reconnaissent avoir eFgé la rédaction en anglais de cette convention (“Agreement”), ainsi que de tous documents exécutés, avis
donnés et procédures judiciaries intentées, directement ou indirectement, relativement à ou suite à la présente convention. 
 Data Privacy Notice and Consent. This provision supplements Section XV of the Agreement: 
 You hereby authorize the Company and the Company’s representative to discuss with and obtain all relevant information from all personnel (professional or not) involved in the administration and
operation of the Plan and the Program. You further authorize the Company and your Employer to disclose and discuss your participation in the Plan with their advisors. You also authorize the Company and your Employer to record such information and
keep it in your employee file. 
 NOTIFICATIONS 
 Securities Law Information. You are permitted to sell Shares acquired through the Plan through the designated broker appointed under the Plan, if any, provided that the resale of such Shares takes
place outside of Canada through the facilities of a stock exchange on which the Shares are listed (i.e., the NASDAQ Global Select Market).  
 CZECH REPUBLIC 
 NOTIFICATIONS 

Exchange Control Information. Proceeds from the sale of shares of Common Stock may be held in a cash account abroad and you
are no longer required to report the opening and maintenance of a foreign account to the Czech National Bank (the “CNB”), unless the CNB notifies you specifically that such reporting is required. Upon request of the CNB, you may need to
file a notification within 15 days of the end of the calendar quarter in which you acquire shares of Common Stock. 

  
 Appendix- 4

 DENMARK 
 NOTIFICATIONS 
 Exchange Control Information. If you
establish an account holding shares or an account holding cash outside Denmark, you must report the account to the Danish Tax Administration. The form which should be used in this respect can be obtained from a local bank. (These obligations are
separate from and in addition to the obligations described below.) 
 Securities/Tax Reporting
Information. If you hold shares of Common Stock acquired under the Plan in a brokerage account with a broker or bank outside Denmark, you are required to inform the Danish Tax Administration about the account. For this purpose, you must
sign and file a Form V (Erklaering V) with the Danish Tax Administration. In the event that the applicable broker or bank with which the account is held does not also sign the Form V, you acknowledge that you are solely responsible for
providing certain details regarding the foreign brokerage or bank account and any shares of Common Stock acquired under the Plan and held in such account to the Danish Tax Administration as part of your annual income tax return. By signing the Form
V, you authorize the Danish Tax Administration to examine the account. 
 In addition, if you open a brokerage account (or a
deposit account with a U.S. bank) for the purpose of holding cash outside Denmark, you are also required to inform the Danish Tax Administration about this account. To do so, you must file a Form K (Erklaering K) with the Danish Tax
Administration. The Form K must be signed both by you and by the applicable broker or bank where the account is held, unless an exemption from the broker/bank signature requirement is obtained from the Danish Tax Administration (which exemption may
be sought on the Form K itself). By signing the Form K, you (and the broker/bank to the extent the exemption is not obtained) undertake an obligation, without further request each year, to forward information to the Danish Tax Administration
concerning the content of the account. By signing the Form K, you authorize the Danish Tax Administration to examine the account. 
 EGYPT

 NOTIFICATIONS 
 Exchange Control Information. If you transfer funds into Egypt in connection with the Performance Units, you are required to transfer the funds through a registered bank in Egypt. 

GERMANY 
 NOTIFICATIONS

 Exchange Control Information. Cross-border payments in excess of €12,500 must be reported monthly to the
German Federal Bank. If you make or receive a payment in excess of this amount, you are responsible for obtaining the appropriate form from a German federal bank and complying with applicable reporting requirements. 

  
 Appendix- 5

 GREECE 
 There are no country-specific provisions. 
 HONG KONG 

TERMS AND CONDITIONS 
 SECURITIES WARNING: The Performance Units and any shares of Common Stock issued in respect of Performance Units do not constitute a public offering of securities under Hong Kong law and are available
only to Participants under the Program. The Agreement, including this Appendix, the Program, the Plan and other incidental communication materials have not been prepared in accordance with and are not intended to constitute a “prospectus”
for a public offering of securities under the applicable securities legislation in Hong Kong, nor have the documents been reviewed by any regulatory authority in Hong Kong. The Performance Units and any documentation related thereto are intended
solely for the personal use of each Participant under the Program and may not be distributed to any other person. If you are in doubt about any of the contents of the Agreement, including this Appendix, the Program or the Plan, you should obtain
independent professional advice. 
 Form of Settlement- Performance Units Payable Only in
Shares. Notwithstanding any discretion in the Plan or the Program or anything to the contrary in the Agreement, the Award does not provide any right for you, as a resident of Hong Kong, to receive a cash payment and shall be paid in shares
of Common Stock only. 
 Sale of Shares of Common Stock. In the event that shares of Common Stock are issued in
respect of Performance Units within six (6) months of the Grant Date, you agree that you will not dispose of such shares prior to the six (6)-month anniversary of the Grant Date. 
 NOTIFICATIONS 
 Nature of Scheme. The Company specifically
intends that the Plan will not be an occupational retirement scheme for purposes of the Occupational Retirement Schemes Ordinance. 

HUNGARY 
 There are no
country-specific provisions. 
 INDIA 
 NOTIFICATIONS 
 Exchange Control Information. You
understand that you must repatriate any cash dividends paid on Shares acquired under the Plan and the Program and any proceeds from the sale of shares of Common Stock acquired under the Plan and the Program to India within 90 days of receipt.

  
 Appendix- 6

 
You will receive a foreign inward remittance certificate (“FIRC”) from the bank where you deposit the foreign currency, and you must maintain the FIRC as proof of repatriation of funds
in the event that the Reserve Bank of India or the Employer requests proof of repatriation. It is your responsibility to comply with these requirements. 
 IRELAND 
 TERMS AND CONDITIONS 

Nature of Grant. This provision supplements Section X of the Agreement: 

In accepting the Award granted hereunder, you acknowledge your understanding and agreement that the benefits received under the Plan will
not be taken into account for any redundancy or unfair dismissal claim. 
 NOTIFICATIONS 

Director Notification Requirements. If you are a director, shadow director or secretary of an Irish Affiliate, you must notify
the Irish Affiliate in writing within five (5) business days of receiving or disposing of an interest in the Company (e.g., an Award or shares of Common Stock) in the Company, or within five (5) business days of becoming aware of
the event giving rise to the notification requirement, or within five (5) business days of becoming a director or secretary if such an interest exists at the time. This notification requirement also applies with respect to the interests of a
spouse or minor children (whose interests, if any, will be attributed to the director, shadow director or secretary). 
 ITALY

 TERMS AND CONDITIONS 
 Data Privacy Notice. The following provision replaces Section XVI of the Agreement: 
 You understand that your Employer, the Company and any Affiliate may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of
birth, social insurance (to the extent permitted under Italian law) or other identification number, salary, nationality, job title, any shares or directorships held in the Company or any Affiliate, details of all Awards granted, or any other
entitlement to shares of Common Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the exclusive purpose of implementing, managing and administering the Plan and the Program (“Data”). 

You also understand that providing the Company with Data is necessary for the performance of the Plan and the Program and that your
refusal to provide such Data would make it impossible for the Company to perform its contractual obligations and may affect your ability to participate in the Plan and the Program. The Controller of personal data processing is Amgen Inc., with
registered offices at One Amgen Center Drive, Thousand Oaks, California 91320, U.S.A., and, pursuant to Legislative Decree no. 196/2003, its Representative in Italy for privacy purposes is Amgen Dompe S.p.A., with registered offices at Via Tazzoli,
6 – 20154 Milan, Italy. 

  
 Appendix- 7

 You understand that Data will not be publicized, but it may be transferred to banks,
other financial institutions, or brokers involved in the management and administration of the Plan and the Program. You understand that Data may also be transferred to the independent registered public accounting firm engaged by the Company. You
further understand that the Company and/or any Affiliate will transfer Data among themselves as necessary for the purposes of implementing, administering and managing your participation in the Plan and the Program, and that the Company and/or any
Affiliate may each further transfer Data to third parties assisting the Company in the implementation, administration, and management of the Plan and the Program, including any requisite transfer of Data to a broker or other third party with whom
you may elect to deposit any shares of Common Stock issued in respect of the Award. Such recipients may receive, possess, use, retain, and transfer Data in electronic or other form, for the purposes of implementing, administering, and managing your
participation in the Plan and the Program. You understand that these recipients may be located in or outside the European Economic Area, such as in the United States or elsewhere. Should the Company exercise its discretion in suspending all
necessary legal obligations connected with the management and administration of the Plan and the Program, it will delete Data as soon as it has completed all the necessary legal obligations connected with the management and administration of the
Plan and the Program. 
 You understand that Data processing related to the purposes specified above shall take
place under automated or non-automated conditions, anonymously when possible, that comply with the purposes for which Data is collected and with confidentiality and security provisions, as set forth by applicable laws and regulations, with specific
reference to Legislative Decree no. 196/2003. 
 The processing activity, including communication, the transfer of
Data abroad, including outside of the European Economic Area, as herein specified and pursuant to applicable laws and regulations, does not require your consent thereto, as the processing is necessary to performance of contractual obligations
related to implementation, administration, and management of the Plan. You understand that, pursuant to Section 7 of the Legislative Decree no. 196/2003, you have the right to, including but not limited to, access, delete, update, correct, or
terminate, for legitimate reason, the Data processing. 
 Furthermore, you are aware that Data will not be used
for direct-marketing purposes. In addition, Data provided can be reviewed and questions or complaints can be addressed by contacting your local human resources representative. 

Acknowledgement of Nature of Grant. By accepting the Award granted hereunder, you acknowledge that (1) you have received a
copy of the Plan, the Program, the Agreement and this Appendix; (2) you have reviewed the applicable documents in their entirety and fully understand the contents thereof; and (3) you accept all provisions of the Plan, the Program, the
Agreement and this Appendix. 

  
 Appendix- 8

 You further acknowledge that you have read and specifically and explicitly approve, without
limitation, the following sections of the Agreement: Section III, Section IV, Section V, Section X, Section IV, Section XVI (as replaced by the above consent), Section XVII and Section XXI. 
 JAPAN 
 There are no country-specific provisions. 

LITHUANIA 
 There are no
country-specific provisions. 
 MEXICO 
 TERMS AND CONDITIONS 
 Acknowledgement of the Grant. In
accepting the Award granted hereunder, you acknowledge that you have received a copy of the Plan and the Program, have reviewed the Plan and the Program and the Agreement, including this Appendix, in their entirety and fully understand and accept
all provisions of the Plan, the Program and the Agreement, including this Appendix. You further acknowledge that you have read and specifically and expressly approve the terms and conditions of Section X of the Agreement, in which the following is
clearly described and established: 
  

	 	(1)	 Your participation in the Plan and the Program do not constitute an acquired right. 

 

	 	(2)	 The Plan and your participation in the Plan and the Program are offered by Amgen Inc. on a wholly discretionary basis. 

 

	 	(3)	 Your participation in the Plan and the Program is voluntary. 

 

	 	(4)	 Amgen Inc. and its Affiliates are not responsible for any decrease in the value of any shares of Common Stock issued with respect to the Award.

 Labor Law Acknowledgement and Policy Statement. In accepting any Award granted hereunder, you
expressly recognize that Amgen Inc., with registered offices at One Amgen Center Drive, Thousand Oaks, California 91320, U.S.A., is solely responsible for the administration of the Plan and that your participation in the Plan and acquisition of
shares of Common Stock do not constitute an employment relationship between you and Amgen Inc. since you are participating in the Plan on a wholly commercial basis and your sole employer is Amgen Latin America Services, S.A. de C.V.
(“Amgen-Mexico”). Based on the foregoing, you expressly recognize that the Plan and the Program and the benefits that you may derive from participation in the Plan and the Program do not establish any rights between you and your Employer,
Amgen-Mexico, and do not form part of the employment conditions and/or benefits provided by Amgen-Mexico and any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.

  
 Appendix- 9

 You further understand that your participation in the Plan and the Program is as a result of
a unilateral and discretionary decision of Amgen Inc.; therefore, Amgen Inc. reserves the absolute right to amend and/or discontinue your participation in the Plan at any time without any liability to you. 

Finally, you hereby declare that you do not reserve to yourself any action or right to bring any claim against Amgen Inc. for any
compensation or damages regarding any provision of the Plan or the benefits derived under the Plan, and you therefore grant a full and broad release to Amgen Inc., its Affiliates, shareholders, officers, agents or legal representatives with
respect to any claim that may arise. 
 Spanish Translation 

Reconocimiento del Otorgamiento. Al aceptar cualquier Otorgamiento de Acciones bajo el presente documento, usted reconoce que
ha recibido una copia del Plan y del Programa, que ha revisado el Plan y el Programa, así como también el Apéndice en su totalidad, además que comprende y está de acuerdo con todas las disposiciones tanto del Plan,
del Programa y del Otorgamiento, incluyendo este Apéndice. Asimismo, usted reconoce que ha leído y manifiesta específicamente y expresamente la conformidad con los términos y condiciones establecidos en la Sección
VIII del Acuerdo del Otorgamiento, en los que se establece y describe claramente que: 
  

	 	(1)	 Su participación en el Plan y en el Programa de ninguna manera constituye un derecho adquirido. 

 

	 	(2)	 Su participación en Plan y en el Programa son ofrecidos por Amgen Inc. de forma completamente discrecional. 

 

	 	(3)	 Su participación en el Plan y en el Programa es voluntaria. 

 

	 	(4)	 Amgen Inc. y sus Afiliados no son responsables de ninguna disminución en el valor de las Acciones Comunes emitidas mediante el Plan.

 Reconocimiento de la Ley Laboral y Declaración de Política. Al aceptar cualquier
Otorgamiento bajo el presente, usted reconoce expresamente que Amgen Inc., con oficinas registradas localizadas en One Amgen Center Drive, Thousand Oaks, California 91320, U.S.A., es la única responsable de la administración del Plan y
que su participación en el mismo y la adquisición de Acciones Comunes no constituyen de ninguna manera una relación laboral entre usted y Amgen Inc., debido a que su participación en el Plan es únicamente una
relación comercial y que su único empleador es Amgen Latin America Services, S.A. de C.V. (“Amgen-Mexico”). Derivado de lo anterior, usted reconoce expresamente que el Plan y el Programa y los beneficios a su favor que
pudieran derivar de la participación en el mismo, no establecen ningún derecho entre usted y su empleador, Amgen – México, y no forman parte de las condiciones laborales y/o los beneficios otorgados por Amgen –
México, y cualquier modificación del Plan o la terminación del mismo no constituirá un cambio o desmejora de los términos y condiciones de su trabajo. 

  
 Appendix- 10

 Asimismo, usted entiende que su participación en el Plan y en el Programa es
resultado de la decisión unilateral y discrecional de Amgen Inc., por lo tanto, Amgen Inc. se reserva el derecho absoluto de modificar y/o descontinuar su participación en el Plan en cualquier momento y sin ninguna responsabilidad para
usted. 
 Finalmente, usted manifiesta que no se reserva ninguna acción o derecho que origine una demanda en contra de
Amgen Inc., por cualquier compensación o daños y perjuicios, en relación con cualquier disposición del Plan o de los beneficios derivados del mismo, y en consecuencia usted exime amplia y completamente a Amgen Inc. de
toda responsabilidad, como así también a sus Afiliadas, accionistas, directores, agentes o representantes legales con respecto a cualquier demanda que pudiera surgir. 
 NETHERLANDS 
 NOTIFICATIONS 

Securities Law Information. You should be aware of Dutch insider-trading rules, which may impact your ability to sell shares
of Common Stock issued in respect of the Award. In particular, you may be prohibited from effectuating certain transactions if you have insider information regarding the Company. 

By accepting the Award granted hereunder and participating in the Plan and the Program, you acknowledge having read and understood this
Securities Law Notification and further acknowledge that it is your responsibility to comply with the following Dutch insider-trading rules: 
 Under Article 5:56 of the Dutch Financial Supervision Act, anyone who has “inside information” related to the issuing company is prohibited from effectuating a transaction in securities in or
from the Netherlands. “Inside information” is defined as knowledge of specific information concerning the issuing company to which the securities relate or the trade in securities issued by such company, which has not been made public, and
which, if published, would reasonably be expected to affect the share price, regardless of the development of the price. The insider could be any employee of an Affiliate in the Netherlands who has inside information as described herein. 

Given the broad scope of the definition of inside information, certain employees of the Company working at an Affiliate in the
Netherlands (including persons eligible to participate in the Plan and the Program) may have inside information and, thus, would be prohibited from effectuating a transaction in securities in the Netherlands at a time when in possession of such
inside information. 

  
 Appendix- 11

 NEW ZEALAND 
 There are no country-specific provisions. 
 NORWAY 

There are no country-specific provisions. 

POLAND 
 NOTIFICATIONS

 Exchange Control Information. Polish residents holding foreign securities (including shares of Common
Stock) and maintaining accounts abroad must report information to the National Bank of Poland. Specifically, if the aggregate value of shares and cash held in such foreign accounts exceeds PLN 7 million, Polish residents must file reports on
the transactions and balances of the accounts on a quarterly basis. If required, the reports are due on a quarterly basis by the 20th day following the end of each quarter and must be filed on special forms available on the website of the National
Bank of Poland. In addition, Polish residents are required to transfer funds through a bank account in Poland if the transferred amount in any single transaction exceeds a specified threshold (currently €15,000). You must store all documents
connected with any foreign exchange transactions you engage in for a period of five years. 
 PORTUGAL 

TERMS AND CONDITIONS 
 Consent to Receive Information in English. You hereby expressly declare that you have full knowledge of the English language and have read, understood and fully accepted and agreed with the terms
and conditions established in the Plan, the Program and Agreement. 
 Conhecimento da Lingua. Por meio do presente, eu
declaro expressamente que tem pleno conhecimento da língua inglesa e que li, compreendi e livremente aceitei e concordei com os termos e condições estabelecidas no Plano, no Programa e no Acordo.  

NOTIFICATIONS 

Exchange Control Information. If you do not hold the shares of Common Stock issued in respect of the Award with a Portuguese
financial intermediary, you will need to file a report with the Portuguese Central Bank. If the shares are held by a Portuguese financial intermediary, it will file the report for you. 
 PUERTO RICO 
 There are no country-specific provisions. 

  
 Appendix- 12

 ROMANIA 
 NOTIFICATIONS 
 Exchange Control Information. If you deposit
proceeds from the sale of shares of Common Stock in a bank account in Romania, you may be required to provide the Romanian bank assisting with the transaction with appropriate documentation explaining the source of the income. You should consult
with a legal advisor to determine whether you will be required to submit such documentation to the Romanian bank. 
 RUSSIA

 TERMS AND CONDITIONS 
 Settlement of Award. Depending on developments in Russian securities regulations, the Company reserves the right, in its sole discretion, to force the immediate sale of any shares of Common
Stock to be issued upon vesting of the Award granted hereunder. You agree that, if applicable, the Company is authorized to instruct Merrill Lynch Bank & Trust Co., FSB (or such other broker as may be designated by the Company) to assist
with the mandatory sale of such shares of Common Stock (on your behalf pursuant to this authorization) and you expressly authorize Merrill Lynch Bank & Trust Co., FSB (or such other broker as may be designated by the Company) to complete
the sale of such shares. You acknowledge that Merrill Lynch Bank & Trust Co., FSB (or such other broker as may be designated by the Company) is under no obligation to arrange for the sale of the shares of Common Stock at any particular
trading price. Upon the sale of shares of Common Stock, you will receive the cash proceeds from the sale of such shares, less any brokerage fees or commissions and subject to your obligations in connection with the Tax Obligations.

 Securities Law Requirements. The Award granted hereunder, the Agreement, including this Appendix, the
Program, the Plan and all other materials you may receive regarding your participation in the Plan and the Program or the Award granted hereunder do not constitute advertising or an offering of securities in Russia. The issuance of shares of Common
Stock in respect of the Award has not and will not be registered in Russia; therefore, such shares may not be offered or placed in public circulation in Russia. 
 In no event will shares of Common Stock acquired under the Plan be delivered to you in Russia; all shares of Common Stock will be maintained on your behalf in the United States. 

You are not permitted to sell any shares acquired under the Plan directly to a Russian legal entity or resident. 

Labor Law Information. You acknowledge that if you continue to hold shares of Common Stock acquired under the Plan after an
involuntary termination of your employment, you will not be eligible to receive unemployment benefits in Russia. 
 NOTIFICATIONS

 Exchange Control Information. Under current exchange control regulations, within a reasonably short time
after sale of the Shares acquired under the Plan and the Program or receipt 

  
 Appendix- 13

 
of dividends on such Shares, you must repatriate the proceeds to Russia. Such proceeds must be initially credited to you through a foreign currency account opened in your name at an authorized
bank in Russia. After the funds are initially received in Russia, they may be further remitted to a foreign bank subject to the following limitations: (i) the foreign account may be opened only for individuals; (ii) the foreign account may
not be used for business activities; (iii) the Russian tax authorities must be given notice about the opening/closing of each foreign account within one month of the account opening/closing; and (iv) the Russian tax authorities must be
given notice of the account balances of such foreign accounts as of the beginning of each calendar year. You are encouraged to contact your personal advisor before remitting your proceeds from participation in the Plan and the Program to Russia as
exchange control requirements may change. 
 SAUDI ARABIA 
 NOTIFICATIONS 
 Securities Law Information. This document may
not be distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Offers of Securities Regulations issued by the Capital Market Authority. 
 The Capital Market Authority does not make any representation as to the accuracy or completeness of this document, and expressly disclaims any liability whatsoever for any loss arising from, or incurred
in reliance upon, any part of this document. You are hereby advised to conduct your own due diligence on the accuracy of the information relating to the shares of Common Stock. If you do not understand the contents of this document, you should
consult an authorized financial adviser. 
 SLOVAK REPUBLIC 
 There are no country-specific provisions. 
 SLOVENIA 

There are no country-specific provisions. 

SOUTH AFRICA 
 TERMS AND
CONDITIONS 
 Responsibility for Taxes. The following provision supplements Section V of the Agreement: 

By accepting the Performance Units, you agree that, immediately upon vesting and settlement of the Performance Units, you will notify
your Employer of the amount of any gain realized. If you fail to advise your Employer of the gain realized upon vesting and settlement, you may be liable for a fine. You will be solely responsible for paying any difference between your actual tax
liability and the amount withheld by your Employer. 

  
 Appendix- 14

 NOTIFICATIONS 
 Exchange Control Information. Because no transfer of funds from South Africa is required under the Performance Units, no filing or reporting requirements should apply when the Performance Units are
granted or when shares of Common Stock are issued upon vesting and settlement of the Performance Units. However, because the exchange control regulations are subject to change, you should consult your personal advisor prior to vesting and settlement
of the Performance Units to ensure compliance with current regulations. You are responsible for ensuring compliance with all exchange control laws in South Africa. 
 SPAIN 
 TERMS AND CONDITIONS 

Labor Law Acknowledgement. The following provision supplements Section X of the Agreement: 

By accepting the Award granted hereunder, you consent to participation in the Plan and the Program and acknowledge that you have received
a copy of the Plan and the Program. 
 You understand that the Company has unilaterally, gratuitously and in its sole discretion
decided to grant the Award under the Plan and the Program to individuals who may be members of the Board, Employees, or Consultants of the Company or its Affiliates throughout the world. The decision is a limited decision that is entered into upon
the express assumption and condition that the Awards granted will not economically or otherwise bind the Company or any of its Affiliates on an ongoing basis, other than as expressly set forth in the applicable Agreement, including this Appendix.
Consequently, you understand that the Award granted hereunder is given on the assumption and condition that it shall not become a part of any employment contract (either with the Company or any of its Affiliates) and shall not be considered a
mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever. Further, you understand and freely accept that there is no guarantee that any benefit whatsoever shall arise from any gratuitous and
discretionary grant of the Award since the future value of the Award and any shares of Common Stock that may be issued in respect of such Award is unknown and unpredictable. In addition, you understand that the Award granted hereunder would not be
made but for the assumptions and conditions referred to above; thus, you understand, acknowledge and freely accept that, should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, then the grant of
the Award or right to the Award shall be null and void. 
 Further, the vesting of the Performance Units is expressly
conditioned your continued and active rendering of service, such that if your employment terminates for any reason whatsoever, the Performance Units may cease vesting immediately, in whole or in part, effective on the date of your termination of
employment (unless otherwise specifically provided in Section I of the Agreement). This will be the case, for example, even if (1) you are considered to be unfairly dismissed without good cause; (2) you are dismissed for disciplinary or
objective reasons or due to a collective dismissal; (3) you terminate service due to a change of work location, duties or 

  
 Appendix- 15

 
any other employment or contractual condition; (4) you terminate service due to a unilateral breach of contract by the Company or an Affiliate; or (5) your employment terminates for any
other reason whatsoever. Consequently, upon termination of your employment for any of the above reasons, you may automatically lose any rights to Performance Units that were not vested on the date of your termination of employment, as described in
the Plan and the Agreement. 
 You acknowledge that you have read and specifically accepts the conditions referred to in Section I of the
Agreement. 
 NOTIFICATIONS 
 Securities Law Information. The Performance Units and the Shares described in the Agreement and this Appendix do not qualify under Spanish regulations as securities. No “offer of
securities to the public,” as defined under Spanish law, has taken place or will take place in the Spanish territory. The Agreement (including this Appendix) has not been nor will it be registered with the
Comisión Nacional del Mercado de Valores, and does not constitute a public offering prospectus.  
 Exchange Control Information. When receiving foreign currency payments exceeding €50,000 derived from the ownership of Shares acquired under the Plan (i.e., dividends or sale proceeds),
you must inform the financial institution receiving the payment of the basis upon which such payment is made. You will need to provide the institution with the following information: (i) your name, address, and fiscal identification number;
(ii) the name and corporate domicile of the Company; (iii) the amount of the payment and the currency used; (iv) the country of origin; (v) the reasons for the payment; and (vi) further information that may be required.

 If you acquire Shares under the Plan, you must declare the acquisition to the Direccion General de Comercio e Inversiones
(“DGCI”). If you acquire the shares through the use of a Spanish financial institution, that institution will automatically make the declaration to the DGCI for you; otherwise, you will be required to make the declaration by filing a
D-6 form. You must also declare ownership of any shares with the DGCI each January while the Shares are owned. 
 SWEDEN

 There are no country-specific provisions. 
 SWITZERLAND 
 NOTIFICATIONS 

Securities Law Notification. The Award offered hereunder is considered a private offering in Switzerland and is, therefore,
not subject to registration in Switzerland. 

  
 Appendix- 16

 TURKEY 
 NOTIFICATIONS 
 Securities Law Information. Under Turkish law,
you are not permitted to sell Shares acquired under the Plan in Turkey. You must sell the Shares acquired under the Plan outside of Turkey. The Shares are currently traded on the NASDAQ in the U.S. under the ticker symbol “AMGN” and Shares
may be sold on this exchange, which is located outside of Turkey. 
 UNITED ARAB EMIRATES 

NOTIFICATIONS 

Securities Law Notice. Performance Units under the Plan are available only to Participants under the Program and are for the
purpose of providing equity incentives. The Plan, the Program and the Agreement are intended for distribution only to such Participants and must not be delivered to, or relied on by, any other person. You should conduct your own due diligence on the
Units offered pursuant to this Agreement. If you do not understand the contents of the Plan and/or the Agreement, you should consult an authorized financial adviser. The Emirates Securities and Commodities Authority and the Dubai Financial Services
Authority have no responsibility for reviewing or verifying any documents in connection with the Plan. Further, the Ministry of the Economy and the Dubai Department of Economic Development have not approved the Plan or the Agreement nor taken steps
to verify the information set out therein, and have no responsibility for such documents. 
 UNITED KINGDOM 

TERMS AND CONDITIONS 
 Tax
Withholding. This provision supplements Section V of the Agreement: 
 You agree that if you do not pay or your Employer or
the Company does not withhold from you the full amount of Tax Obligations that you owe due at issuance of shares of Common Stock in respect of the Performance Units, or the release or assignment of the Performance Units for consideration, or the
receipt of any other benefit in connection with the Performance Units (the “Taxable Event”) within 90 days after the Taxable Event, or such other period specified in Section 222(1)(c) of the U.K. Income Tax (Earnings and Pensions) Act
2003, then the amount that should have been withheld and/or paid shall constitute a loan owed by you to your Employer, effective 90 days after the Taxable Event. You agree that the loan will bear interest at the official rate of HM Revenue and
Customs (“HMRC”) and will be immediately due and repayable by you, and the Company and/or your Employer may recover it at any time thereafter by withholding (subject to Section V of the Agreement) the funds from salary, bonus or any other
funds due to you by your Employer, by withholding in shares of Common Stock issued in respect of the Performance Units or from the cash proceeds from the sale of shares of Common Stock or by demanding cash or a check from you. You also authorize the
Company to delay the issuance of any shares of Common Stock to you unless and until the loan is repaid in full. 

Notwithstanding the foregoing, if you are an officer or executive director (as within the meaning of Section 13(k) of the Exchange
Act, as amended), from time to time, the terms of the 

  
 Appendix- 17

 
immediately foregoing provision will not apply. In the event that you are an officer or executive director and Tax Obligations are not collected from or paid by you within 90 days of the Taxable
Event, the amount of any uncollected Tax Obligations may constitute a benefit to you on which additional income tax and national insurance contributions may be payable. You acknowledge that you are responsible for reporting and paying these
potential additional taxes under the self-assessment regime. 
 Joint Election. As a condition of the Award, you agree to
accept any liability for secondary Class 1 National Insurance Contributions (the “Employer NICs”) which may be payable by the Company or your Employer with respect to the earning and/or payment of the Performance Units and issuance of
shares of Common Stock in respect of the Performance Units, the assignment or release of the Performance Units for consideration or the receipt of any other benefit in connection with the Performance Units. 

Without limitation to the foregoing, you agree to make an election (the “Election”), in the form specified and/or approved for
such election by HMRC, that the liability for your employer NICs payments on any such gains shall be transferred to you to the fullest extent permitted by law. You further agree to execute such other elections as may be required between you and any
successor to the Company and/or your Employer. You hereby authorize the Company and your Employer to withhold such Employer NICs by any of the means set forth in Section V of the Agreement. 

Failure by you to enter into an Election, withdrawal of approval of the Election by HMRC or a joint revocation of the Election by you and
the Company or your Employer, as applicable, shall be grounds for the forfeiture and cancellation of the Performance Units, without any liability to the Company or your Employer. 
 UNITED STATES 
 TERMS AND CONDITIONS 

Nature of Grant. The following provision replaces Section X(j) of the Award Agreement: 

(j) in the event of termination of your employment (whether or not in breach of local labor laws), your right to receive Performance
Units and receive shares under the Plan and the Program, if any, will terminate effective as of the date that you are no longer actively employed; provided, however, that such right will be extended by any notice period mandated by law
(e.g. the Worker Adjustment and Retraining Notification Act (“WARN Act”) notice period or similar periods pursuant to local law) and any paid administrative leave (as applicable), unless the Company shall provide you with written notice
otherwise before the commencement of such notice period or leave. In such event, payment of the Performance Units shall be made in accordance with Section IV. 

  
 Appendix- 18Amendment No.5 to the Development and License Agreement

 Exhibit 10.1 

AMENDMENT NO. 5 TO DEVELOPMENT AND LICENSE AGREEMENT 
 This Amendment No. 5 (the “Amendment”), dated June 21, 2012, is entered into by and between Abbott Diabetes Care Inc., formerly known as TheraSense, Inc.
(“ADC”), and Insulet Corporation (“Insulet”), to amend the Development and License Agreement entered into between TheraSense, Inc. (“Therasense”) and Insulet, effective as of January 23, 2002,
as previously amended on March 3, 2008, June 30, 2010, April 5, 2011 and March 29, 2012 (together with this Amendment No. 5 hereinafter referred to collectively as the “Agreement”). Capitalized
terms used herein but not otherwise defined shall have the meanings ascribed to them in the Agreement. 
 NOW, THEREFORE, in
consideration of the premises and mutual covenants contained in this Amendment and in the Agreement, ADC and Insulet hereby agree as follows: 
  

	 	1.	Effective upon commencement of the Extension Term, Section 1.25 is amended to delete Israel from the definition of “Territory” and Section 1.37 is
hereby amended to add Israel to the definition of “Expansion Territory.” 

  

	 	2.	Section 7.1 is hereby amended and restated in its entirety to read as follows: 

7.1 Term. This Agreement shall remain in effect until March 3, 2013, or until terminated in accordance with
the provisions of this Article VII (the “Initial Term”). At the end of the Initial Term, this Agreement shall be renewed for an extension term that will expire on December 31, 2014, on a non-exclusive basis, unless sooner
terminated in accordance with the provisions of this Article VII (“Extension Term”). At the end of the Extension Term, this Agreement shall continue solely for the purposes of Section 10.4 and Articles XII and XIII, for a term
that will expire on December 31, 2015, unless terminated in accordance with the provisions of this Article VII (“Post-Expiration Period”). 
  

	 	3.	Section 7.4(a) is hereby deleted in its entirety and replaced with the following: 

(a) Upon any termination of this Agreement pursuant to Section 7.2, Insulet shall within thirty (30) days of
the effective date of such termination notify ADC of the amount of Products with ADC DBGM that Insulet, its Affiliates and distributors then have completed on hand, and Insulet, its Affiliates and distributors shall thereupon be permitted during the
six months following such termination to sell that amount of such Products (provided, however, that if such termination is during the Extension Term, such time period to sell such Products shall be during the six months following such termination or
until December 31, 2014, whichever is earlier). All licenses granted pursuant to Article V shall remain in effect until the last sale of such Products or the expiration of such six-month period (whichever is earlier) (provided, however, that if
such termination is during the Extension Term, such licenses will remain in effect until the earlier of (i) the last sale of such Products, (ii) the expiration of such six-month period, or (iii) December 31, 2014). 

 

	 	4.	Section 7.4(b) is hereby deleted in its entirety and replaced with the following: 

(b) Upon the termination of this Agreement pursuant to Section 7.2, ADC shall notify Insulet of the amount of Test
Strips that ADC has on hand that bear any Insulet Marks, and ADC and its Affiliates and Distributors shall thereupon be permitted during the six months following such termination to sell that amount of Test Strips with Insulet Marks (provided,
however, that if such termination is during the Extension Term, such time period to sell Test Strips with Insulet Marks shall be during the six months following such termination or until December 31, 2014, whichever is earlier). ADC may sell
Test Strips without restriction upon removal of all Insulet Marks. The license granted pursuant to Section 5.4(b) shall remain in effect until the last sale of the Test Strips with Insulet Marks or all the expiration of such six-month period
(whichever is earlier) (provided, however, that if such termination is during the Extension Term, such licenses will remain in effect until the earlier of (i) the last sale of the Test Strips with Insulet Marks, (ii) the expiration of such
six-month period, or (iii) December 31, 2014). 

	 	5.	A new Section 7.4(d) is hereby added to read as follows: 

 (d) Upon termination of the Extension Term of this Agreement pursuant to Section 7.1, the licenses granted pursuant to Article V shall remain in force to the extent necessary for Insulet to produce
and distribute Products with an ADC DBGM for the limited purposes specified in Section 12.1(b). Upon termination of the Post-Expiration Period of this Agreement pursuant to Section 7.1, all licenses granted pursuant to Article V shall
immediately terminate and Insulet shall have no right to produce, sell or distribute any Product that includes an ADC DBGM and ADC shall have no right to sell the Test Strips with Insulet Marks. 

 

	 	6.	Section 7.7 is hereby deleted. 

  

	 	7.	A new Section 7.8 is hereby added to read as follows: 

 7.8 Termination by ADC. In the event that: (a) there is more than [***********] decline in the Audited Baseline (as defined in Section 10.4(c)) from one Semi-Annual Period (as defined in
Section 10.4(b)) to the next Semi-Annual Period; (b) there is more than [***********] cumulative decline from the Initial Baseline (as defined in Section 10.4(a)); or (c) Insulet breaches any of its obligations under
Section 10.4 or Article XII, ADC may immediately terminate this Agreement upon written notice to Insulet (without regard to any cure period specified in this Article VII). Without limitation of any legal or equitable remedies that may be
available to ADC, upon termination pursuant to this Section 7.8, (i) no further payments will be owed by ADC to Insulet for the period during which the percentage threshold set forth in clause (a) or (b) above was crossed;
(ii) Insulet’s obligations pursuant to Article XII shall immediately terminate; and (iii) any amounts owed by Insulet to ADC pursuant to this Agreement will be immediately payable to ADC. For the avoidance of doubt while a decline in
the Audited Baseline or from the Initial Baseline as described above gives ADC a right to terminate this Agreement under this Section 7.8, a decline in the Audited Baseline or Initial Baseline by itself, regardless of the extent of the decline,
so long as the decline is not attributable to any actions by Insulet that are inconsistent with other provisions of this Agreement, shall not be considered a breach of this Agreement by Insulet, and in such event ADC shall have no right to any legal
or equitable remedies other than termination of this Agreement and discontinuation of payments as described in this Section 7.8. 
  

	 	8.	A new sentence is added to the end of Section 9.4 as follows: “This Section 9.4 shall apply to Customer Service Events in the Expansion Territory during
the Initial Term only, and it is hereby agreed between ADC and Insulet that [***********] for any Expansion Territory Customer Service Events will be owed during the Extension Term or Post-Expiration Period under this Agreement.”

  

	 	9.	Section 9.5 is hereby amended to: (i) delete all references to Israel, effective upon commencement of the Extension Term; (ii) add the following
parenthetical after the terms “[****************]”: “[*************************************************************** **************************************************************************]”; and (iii) add the
following sentence to the end of the section: “[*************************************** *****************************************************************************
*************************************************************************************]” 

  

	 	10.	Section 10.3 is hereby amended to delete all references to Israel, effective upon commencement of the Extension Term. 

 

	 	11.	A new Section 10.4 is hereby added to read as follows: 

 10.4 Audits and Reports during the Extension Term and Post-Expiration Period. In addition to the other provisions of this Article X, the following provisions shall apply during the Extension Term
and Post-Expiration Period: 

  
 2 

 (a) ADC shall engage an independent auditor to conduct an audit of
Insulet’s existing base of Existing Customers and NextGen Customers (both as defined in Section 12.2(a)) as of [*******], the results of which shall establish the “Initial Baseline.” Such initial audit shall include a list
of individual Existing Customers and NextGen Customers as of [*******], identified by non-personally-identifiable tracking numbers. Such Audit shall be completed by [**********] or, if later, [**********] after the date on which all documents,
records or agreements reasonably necessary to conduct the initial audit are made available to ADC’s auditor. 
 (b) Within [************] after the end of [***************] (each a “Semi-Annual Period”) commencing [************] and ending on the last date of the Post-Expiration Period, Insulet
shall provide ADC with a report (the “Customer Report”) that contains the following data for such Semi-Annual Period: 
  

	 	(i)	[*************************************************************************************** ***************************************]; 

 

	 	(ii)	[*************************************************************************************** ***************************************]; and 

 

	 	(iii)	[***************************************************************************************
**************************************************************************************** *************************************************************************************** ***************************]. 

The Semi-Annual Period ending on the last date of the Post-Expiration Period, even though such period is less than [************], is
considered a Semi-Annual Period for purposes of this Agreement. 
 (c) ADC shall engage an independent auditor
to conduct an audit of each Customer Report, which must be completed within [************] after ADC’s receipt of the complete applicable Customer Report or, if later, the date on which all documents, records or agreements necessary to conduct
the audit are made available to ADC’s auditor. The results of each audit shall establish the “Audited Baseline” as of the last day of the applicable Semi-Annual Period, and such Audited Baseline shall become the
“Baseline” as of the first day of the next Semi-Annual Period. 
 (d) Insulet shall fully
cooperate with ADC with respect to such audits, including but not limited to ensuring that all necessary documents, records and agreements necessary to conduct all audits are available to ADC’s designated independent auditors on the date the
Customer Report is provided to ADC. 

(e) [*************************************************************************************]. 

(f) Prior to commencing any audit pursuant to this Section 10.4, ADC’s independent auditor shall enter into a
Business Associate Agreement with Insulet compliant with the Health Insurance Portability and Accountability Act, or other appropriate agreement protecting the personally identifiable information, unless an auditor has already entered into such an
agreement with Insulet with respect to a previous audit. Such agreement will provide that under no circumstances may ADC’s independent auditor provide to ADC personally identifiable information of Insulet customers. 

(g) With respect to Existing Customers and NextGen Customers located in Canada, ADC’s audit rights under this
Section 10.4 will be limited to examining OmniPod tracking summary reports provided to Insulet by its Canadian distributor, which shall be substantially in the form of Schedule E attached hereto. Such report(s) for the relevant time periods
will be made available to ADC’s auditor at the time of each audit under this Section 10.4. 

  
 3 

	 	12.	A new Article XII is hereby added to read as follows: 

 Article XII 
 12.1 Additional Insulet Obligations.

 (a) As soon as reasonably practicable after it receives regulatory approval and is available for sale in
the United States and Canada, Insulet may upgrade all Existing Customers (as defined in Section 12.2(a)) who are located in the United States and Canada, respectively, to Insulet’s next generation Remote Controller that incorporates a
FreeStyle Glucose Engine and FreeStyle Strip port (“NextGen FS PDM”) and that will work in conjunction with Insulet’s next generation OmniPod “Eros” system, which shall be considered a Product under this Agreement.
Existing Customers who are upgraded to the NextGen FS PDM shall thereafter be referred to as “NextGen Customers.” 
 (b) During the Post-Expiration Period, Insulet may continue to manufacture and distribute Products with an ADC DBGM solely for warranty replacement purposes throughout the Territory. 

12.2 Additional Insulet Restrictions. 

(a) Insulet shall not, directly or indirectly, and shall not assist, directly or indirectly, any third party (e.g.,
any Competitor of ADC) to, actively switch any customers who are located in the U.S. and who are currently using a Remote Controller with an ADC DBGM (“Existing Customers”) or any NextGen Customers to any Remote Controller with a
DBGM other than the ADC DBGM (an “Alternative PDM”) before the end of the Post-Expiration Period (which includes the Initial Term, Extension Term and Post-Expiration Period). For purposes of this Section 12.2(a), “actively
switch” shall mean outbound communication of any kind from Insulet or its Affiliates (or any contractors, distributors or agents acting under the direction or control of Insulet or its Affiliates) intended to (or that would reasonably be
interpreted as intending to) encourage, convince or otherwise solicit an Existing Customer or a NextGen Customer in any way to switch to or request an Alternative PDM. For purposes of this Section 12.2(a), “assist any third party”
shall mean any activity that is intended to (or that would reasonably be interpreted as intending to) assist, cause, enable, encourage or incentivize a third party to actively switch an Existing Customer or a NextGen Customer to an Alternative PDM,
including but not limited to providing Existing Customer or NextGen Customer lists to such third parties or approving the third parties’ promotional materials targeting Existing Customers or NextGen Customers. 

(b) Notwithstanding the foregoing restrictions in Section 12.2(a), Insulet may engage in marketing activities
(e.g., without limitation, magazine advertisements, websites, physician office detailing, etc.) to promote an Alternative PDM that do not specifically target Existing Customers or NextGen Customers, but may reach Existing Customers or NextGen
Customers incidentally (as further described below), provided that such marketing activities shall not include any comparisons between an Alternative PDM and the Product with ADC DBGM (including the NextGen FS PDM), including without limitation, any
claims promoting preferential co-pays, greater accuracy or other features of the Alternative PDM over the Product with ADC DBGM (including the NextGen FS PDM). For purposes of this paragraph, mass mailings, emails or other direct communications (as
opposed to non-targeted general marketing or advertising activities) will be deemed to reach Existing Customers or NextGen Customers “incidentally” only: (i) if they are not communicated directly by or from Insulet (or any
contractors, distributors or agents acting under the direction or control of Insulet or its Affiliates); or (ii) if Insulet communicates marketing materials indirectly through a third party who is not a Competitor of ADC (i.e., a
co-promotion partner) to such third party’s proprietary database of customers or 

  
 4 

 
members, Insulet shall ensure that such communications are not delivered to Existing Customers or NextGen Customers; and if Insulet is unable to ensure that such communications will not be
delivered to Existing Customers or NextGen Customers, then such communications may only promote Insulet’s products generally or Insulet’s Products with ADC DBGM and may not prominently feature or promote the brand of blood glucose meter in
an Alternate PDM. Insulet may provide an Alternative PDM to any Existing Customer or NextGen Customer who makes a unilateral and unsolicited request for an Alternative PDM. 

(c) Insulet shall not: (i) enter into any arrangement with any third party; (ii) exercise any rights under
existing arrangements with third parties; or (iii) take (or refrain from taking) any other action that would conflict or be inconsistent in any way with or result in the breach of any of the provisions of Sections 12.2(a) and (b). 

12.3 Additional ADC Obligations. ADC shall use commercially reasonable efforts to complete laboratory verification
testing of ADC’s currently marketed FreeStyle Test Strip in connection with the NextGen FS PDM in accordance with ISO 1519 within an estimated [************] after the later of the date on which ADC receives (a) approval to proceed with
the testing, and (b) all necessary materials from Insulet to conduct such testing, including but not limited to the appropriate Remote Controllers. Insulet shall reimburse ADC for all costs and expenses incurred in such testing, which shall be
payable to ADC within [************] after ADC’s invoice of such expenses to be issued upon completion of such testing. ADC shall provide an estimate of such costs and expenses to Insulet before testing begins, provided that such estimate shall
be an estimate in good faith only and Insulet shall be obligated to reimburse ADC in accordance with the actual costs and expenses as set forth on the invoice. 
  

	 	13.	A new Article XIII is hereby added to read as follows: 

 Article XIII 
 13.1 Renewal Fee. ADC shall make a
renewal fee payment to Insulet in the amount of [*********************], as adjusted pursuant to this Article XIII, payable in pro-rata semi-annual installments during the Extension Term and Post-Expiration Period based on the calculation set forth
in Section 13.2 and at the times set forth in Section 13.3 (each a “Semi-Annual Payment”). 
 13.2 Semi-Annual Payment Calculation. 
 (a) The calculation
of each Semi-Annual Payment will be determined in accordance with the following formula: 

[**********************************] 

(b) For purposes of the calculation set forth in Section 13.2(a), the following terms have the following meanings:

  

	 	(i)	[**********************************************************************************
    *********************************************************************************     *****************************************************************]. 

 

	 	(ii)	[**********************************************************************************     ******************************************].

 (c) By way of example (for non-binding illustrative purposes only), the Semi-Annual Payment for
the Semi-Annual Period ending on March 31, 2014 would be [***********] under the following hypothetical circumstances: 

  
 5 

	 	(i)	[***********************************] 

  

	 	(ii)	[***********************************] 

  

	 	(iii)	[***********************************] 

  

	 	(iv)	[***********************************] 

  

	 	(v)	[***********************************] 

  

	 	(vi)	[***********************************] 

 13.3 Timing for Semi-Annual Payment. ADC shall pay to Insulet each Semi-Annual Payment during the Extension Term and Post-Expiration Period within [*********] after ADC’s receipt of the
corresponding Customer Report or, if later, the date on which all documents, records or agreements necessary to conduct the audit pursuant to Section 10.4 are made available to ADC’s auditor. Any adjustments required to be made to a
Semi-Annual Payment pursuant to Section 10.4(e) shall be in the form of a credit against the next Semi-Annual Payment; and in the case of the final Semi-Annual Payment, a refund, which shall be payable to ADC within [*********] after the date
of notification from ADC to Insulet identifying such required adjustment. 
  

	 	14.	On the sooner of (a) [*********], or (b) such other date mutually agreed by the parties, ADC may issue a press release relating to this Amendment No. 5,
which press release shall be in the form mutually agreed upon by the parties, and such agreement shall not be unreasonably withheld, conditioned or delayed by either party. 

 

	 	15.	Except as specifically modified or amended hereby, the Agreement shall remain in full force and effect, and as so modified or amended, is hereby approved. No provision
of this Amendment may be modified or amended except expressly in a writing signed by both parties. 

  
 6 

 *    *     * 

IN WITNESS WHEREOF, the parties have caused this Amendment No. 5 to Development and License Agreement to be signed by a duly
authorized representative effective as of the date set forth above. 
  

									
	INSULET CORPORATION	 		 	ABBOTT DIABETES CARE INC.
					
	By:	 	/s/ Duane DeSisto	 		 	By:	 	/s/ Heather Mason
	Name:	 	Duane DeSisto	 		 	Name:	 	Heather Mason
	Title:	 	CEO	 		 	Title:	 	President

  
 7 

 SCHEDULE E 
 Canada - OmniPod Tracking Summary 
  

													
	 Patient
     ID
	  	Patient
Start Date	 	  	PDM Shipment
Date	 	  	Last Pod
Shipment 
Date	 
	 14326
	  	 	******	  	  	 	******	  	  	 	******	  
	 14475
	  	 	******	  	  	 	******	  	  	 	******	  
	 14482
	  	 	******	  	  	 	******	  	  	 	******	  
	 14557
	  	 	******	  	  	 	******	  	  	 	******	  
	 14561
	  	 	******	  	  	 	******	  	  	 	******	  
	 14565
	  	 	******	  	  	 	******	  	  	 	******	  
	 14568
	  	 	******	  	  	 	******	  	  	 	******	  
	 14595
	  	 	******	  	  	 	******	  	  	 	******	  
	 14617
	  	 	******	  	  	 	******	  	  	 	******	  
	 14620
	  	 	******	  	  	 	******	  	  	 	******	  
	 14622
	  	 	******	  	  	 	******	  	  	 	******	  
	 14626
	  	 	******	  	  	 	******	  	  	 	******	  
	 14629
	  	 	******	  	  	 	******	  	  	 	******	  
	 14632
	  	 	******	  	  	 	******	  	  	 	******	  
	 14649
	  	 	******	  	  	 	******	  	  	 	******	  
	 14651
	  	 	******	  	  	 	******	  	  	 	******	  
	 14653
	  	 	******	  	  	 	******	  	  	 	******	  
	 14668
	  	 	******	  	  	 	******	  	  	 	******	  
	 14688
	  	 	******	  	  	 	******	  	  	 	******	  
	 14700
	  	 	******	  	  	 	******	  	  	 	******	  
	 14729
	  	 	******	  	  	 	******	  	  	 	******	  
	 14732
	  	 	******	  	  	 	******	  	  	 	******	  
	 14738
	  	 	******	  	  	 	******	  	  	 	******	  
	 14751
	  	 	******	  	  	 	******	  	  	 	******	  
	 14762
	  	 	******	  	  	 	******	  	  	 	******	  
	 14763
	  	 	******	  	  	 	******	  	  	 	******	  
	 14779
	  	 	******	  	  	 	******	  	  	 	******	  
	 14808
	  	 	******	  	  	 	******	  	  	 	******	  
	 14828
	  	 	******	  	  	 	******	  	  	 	******	  
	 14831
	  	 	******	  	  	 	******	  	  	 	******	  
	 14837
	  	 	******	  	  	 	******	  	  	 	******	  
	 14853
	  	 	******	  	  	 	******	  	  	 	******	  
	 14863
	  	 	******	  	  	 	******	  	  	 	******

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00206-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00206-of-00352.parquet"}]]